Abstract
The risk of maturation failure in arteriovenous fistula (AVF) remains high. Curcumin poses antioxidant effects may enhance AVF maturation. This study evaluates the antioxidant effect of Curcumin on AVF maturation among type 2 diabetic patients (T2DM) with end-stage renal disease (ESRD). This was a single-blinded, randomized controlled trial conducted in three tertiary hospitals in Jakarta, Indonesia. Patients underwent the first hemodialysis. A total of 67 patients divided into groups of Curcumin, acetylsalicylic acid, and placebo. After 4 weeks, TAC level among the curcumin group was significantly higher compared to acetylsalicylic acid, and placebo groups 794.2(457.4±1473.7) µM vs. 519.2(247.7 ± 1027.7) µM and 794.2(457.4± 1473.7) µM vs. 542.5(281.91± 1054.64) µM, respectively (p<0.05). Also, TAC after 8 weeks was significantly higher among curcumin group compared to acetylsalicylic acid, and placebo groups (820.5(380.7± 1643.7) µM vs. 509.7(341.0± 981.91) µM and 820.5(380.7± 1643.7) µM vs. 497.7(324.7± 979.2) µM, respectively (p<0.001). The TAC level patients with mature AVF were also higher. A 2000 mg/day of curcumin increases antioxidant capacity after 4 and 8 weeks following AVF surgery among ESRD with T2DM.
Full text article
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.